CVS Health Corp is a diversified healthcare company that operates a vast network of retail pharmacies, providing prescription medications, over-the-counter products, and health and wellness services. In addition to its retail operations, CVS Health also offers pharmacy benefit management services, helping manage prescription drug costs for businesses and health plans. The company is involved in providing health insurance and health services through its various divisions, including a growing presence in digital health solutions and immunization services. By integrating pharmacy services with healthcare delivery, CVS Health aims to enhance patient care and improve health outcomes across the communities it serves. Read More
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Humana (NYSE:HUM).
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Elevance Health (NYSE:ELV) and its peers.
Synergy CHC Corp. (NASDAQ: SNYR) is supercharging its retail expansion with a nationwide rollout of FOCUSfactor® Focus + Energy through EG America, the 6th largest U.S. convenience chain . The deal instantly places the functional brain health beverage in 1,600+ high-traffic locations , including Cumberland Farms, Turkey Hill, Tom Thumb (Albertsons Companies Inc. – NYSE: ACI), Loaf ’N Jug, and Minit Mart .
In a striking display of market intervention and strategic investment, two major corporate developments are sending ripples through the financial world. The U.S. government is reportedly considering an unprecedented ownership stake in struggling chipmaker Intel (NASDAQ: INTC), signaling a direct and significant move to bolster domestic semiconductor manufacturing. Simultaneously,
The financial markets are grappling with a perplexing economic puzzle as recent inflation data presents a contradictory picture. July 2025 saw the Producer Price Index (PPI) surge significantly, indicating rising wholesale costs for businesses, while the Consumer Price Index (CPI) remained relatively steady. This divergence has sent mixed signals to
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Looking back on health insurance providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Cigna (NYSE:CI) and its peers.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including AMN Healthcare Services (NYSE:AMN) and its peers.
Synergy CHC Corp. (NASDAQ: SNYR), a consumer health and wellness company, has reported its financial results for Q2 2025, marking its tenth consecutive quarter of profitability . The company posted revenue of $8.1 million, gross margin of 76.7%, and net income of $1.5 million—up 125% year-over-year—with earnings per share rising 86% to $0.17. EBITDA surged 136% to $3.8 million. See Entire Press Release.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Cencora (NYSE:COR) and the rest of the health insurance providers stocks fared in Q2.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Pediatrix Medical Group (NYSE:MD) and its peers.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CVS (CVS) To Contact Him Directly To Discuss Their Options
Diversified healthcare company CVS Health (NYSE:CVS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Synergy CHC Corp. (NASDAQ: SNYR), the consumer health powerhouse behind the FOCUSfactor® brand, is making headlines again as its CEO took to the airwaves to spotlight the company’s 25-year journey from brain-boosting tablets to energy drinks and weight management innovation.
